vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Commercial Vehicle Group, Inc. (CVGI). Click either name above to swap in a different company.
Commercial Vehicle Group, Inc. is the larger business by last-quarter revenue ($154.8M vs $139.2M, roughly 1.1× ADMA BIOLOGICS, INC.). On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -5.2%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $8.7M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -10.8%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
WABCO Holdings, Inc. was a U.S.-based provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. In 2007, the Vehicle Control Systems was spun off as WABCO Holdings Inc., an American provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. Their products are present in many commercial vehicles such as trucks, buses, trailers and off-highway vehicles but they ...
ADMA vs CVGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $154.8M |
| Net Profit | $49.4M | — |
| Gross Margin | 63.8% | 9.7% |
| Operating Margin | 45.1% | -1.2% |
| Net Margin | 35.5% | — |
| Revenue YoY | 18.4% | -5.2% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $154.8M | ||
| Q3 25 | $134.2M | $152.5M | ||
| Q2 25 | $122.0M | $172.0M | ||
| Q1 25 | $114.8M | $169.8M | ||
| Q4 24 | $117.5M | $163.3M | ||
| Q3 24 | $119.8M | $171.8M | ||
| Q2 24 | $107.2M | $193.7M | ||
| Q1 24 | $81.9M | $194.6M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $-7.1M | ||
| Q2 25 | $34.2M | $-4.8M | ||
| Q1 25 | $26.9M | $-4.3M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $9.5M | ||
| Q2 24 | $32.1M | $-1.6M | ||
| Q1 24 | $17.8M | $2.9M |
| Q4 25 | 63.8% | 9.7% | ||
| Q3 25 | 56.3% | 10.5% | ||
| Q2 25 | 55.1% | 11.4% | ||
| Q1 25 | 53.2% | 10.5% | ||
| Q4 24 | 53.9% | 8.0% | ||
| Q3 24 | 49.8% | 9.6% | ||
| Q2 24 | 53.6% | 10.6% | ||
| Q1 24 | 47.8% | 11.9% |
| Q4 25 | 45.1% | -1.2% | ||
| Q3 25 | 38.0% | -0.7% | ||
| Q2 25 | 35.1% | 0.5% | ||
| Q1 25 | 30.4% | 0.8% | ||
| Q4 24 | 32.6% | -3.2% | ||
| Q3 24 | 33.1% | -0.6% | ||
| Q2 24 | 36.6% | 0.5% | ||
| Q1 24 | 26.7% | 2.3% |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | -4.6% | ||
| Q2 25 | 28.1% | -2.8% | ||
| Q1 25 | 23.4% | -2.5% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | 5.5% | ||
| Q2 24 | 29.9% | -0.8% | ||
| Q1 24 | 21.7% | 1.5% |
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.15 | — | ||
| Q2 24 | $0.13 | $-0.05 | ||
| Q1 24 | $0.08 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | $104.9M |
| Stockholders' EquityBook value | $477.3M | $133.4M |
| Total Assets | $624.2M | $391.7M |
| Debt / EquityLower = less leverage | 0.15× | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — | ||
| Q1 24 | $45.3M | — |
| Q4 25 | $72.1M | $104.9M | ||
| Q3 25 | $72.4M | $108.2M | ||
| Q2 25 | — | $118.2M | ||
| Q1 25 | — | $117.4M | ||
| Q4 24 | $72.3M | $135.5M | ||
| Q3 24 | — | $128.8M | ||
| Q2 24 | — | $142.0M | ||
| Q1 24 | — | $155.7M |
| Q4 25 | $477.3M | $133.4M | ||
| Q3 25 | $431.2M | $136.5M | ||
| Q2 25 | $398.3M | $142.6M | ||
| Q1 25 | $373.4M | $136.7M | ||
| Q4 24 | $349.0M | $135.6M | ||
| Q3 24 | $231.9M | $179.3M | ||
| Q2 24 | $188.3M | $169.6M | ||
| Q1 24 | $153.7M | $175.5M |
| Q4 25 | $624.2M | $391.7M | ||
| Q3 25 | $568.7M | $400.3M | ||
| Q2 25 | $558.4M | $429.8M | ||
| Q1 25 | $510.6M | $419.8M | ||
| Q4 24 | $488.7M | $424.6M | ||
| Q3 24 | $390.6M | $495.3M | ||
| Q2 24 | $376.4M | $503.2M | ||
| Q1 24 | $350.9M | $509.2M |
| Q4 25 | 0.15× | 0.79× | ||
| Q3 25 | 0.17× | 0.79× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | 0.21× | 1.00× | ||
| Q3 24 | — | 0.72× | ||
| Q2 24 | — | 0.84× | ||
| Q1 24 | — | 0.89× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $12.3M |
| Free Cash FlowOCF − Capex | $34.6M | $8.7M |
| FCF MarginFCF / Revenue | 24.8% | 5.6% |
| Capex IntensityCapex / Revenue | 0.8% | 2.3% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $34.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $12.3M | ||
| Q3 25 | $13.3M | $-1.7M | ||
| Q2 25 | $21.1M | $18.9M | ||
| Q1 25 | $-19.7M | $15.2M | ||
| Q4 24 | $50.2M | $-26.6M | ||
| Q3 24 | $25.0M | $-17.1M | ||
| Q2 24 | $45.6M | $12.6M | ||
| Q1 24 | $-2.2M | $-2.4M |
| Q4 25 | $34.6M | $8.7M | ||
| Q3 25 | $-1.1M | $-3.5M | ||
| Q2 25 | $18.7M | $17.4M | ||
| Q1 25 | $-24.4M | $11.4M | ||
| Q4 24 | $47.5M | $-30.6M | ||
| Q3 24 | $24.0M | $-20.3M | ||
| Q2 24 | $43.6M | $6.4M | ||
| Q1 24 | $-4.6M | $-7.4M |
| Q4 25 | 24.8% | 5.6% | ||
| Q3 25 | -0.8% | -2.3% | ||
| Q2 25 | 15.3% | 10.1% | ||
| Q1 25 | -21.2% | 6.7% | ||
| Q4 24 | 40.4% | -18.7% | ||
| Q3 24 | 20.0% | -11.8% | ||
| Q2 24 | 40.7% | 3.3% | ||
| Q1 24 | -5.6% | -3.8% |
| Q4 25 | 0.8% | 2.3% | ||
| Q3 25 | 10.7% | 1.2% | ||
| Q2 25 | 2.0% | 0.9% | ||
| Q1 25 | 4.1% | 2.2% | ||
| Q4 24 | 2.3% | 2.4% | ||
| Q3 24 | 0.9% | 1.9% | ||
| Q2 24 | 1.9% | 3.2% | ||
| Q1 24 | 2.9% | 2.6% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | -1.79× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | -0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
CVGI
| Global Seating | $70.7M | 46% |
| Global Electrical Systems | $49.7M | 32% |
| Trim Systems And Components | $34.4M | 22% |
